ArticleCase reports in neurological medicine2025
Cytomegalovirus Infection in a Multiple Sclerosis Patient on Dimethyl Fumarate.
Article in Case reports in neurological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between cytomegalovirus (CMV) infection and multiple sclerosis (MS) remains unclear. CMV infection has been reported in MS patients treated with alemtuzumab, rituximab, and ocrelizumab, but its occurrence in patients receiving dimethyl fumarate (DMF) is less studied. Objectives: This case report explores the potential relationship between DMF therapy and CMV infection in a relapsing-remitting MS (RRMS) patient, examining whether DMF-induced immune modulation contributed to CMV reactivation or primary infection. Results: A 29-year-old male with RRMS, on DMF for four years without lymphopenia, developed elevated liver enzymes and splenomegaly. CMV serology showed IgG (60.7 U/L) and IgM (140.0 U/L), with detectable viral DNA (524 IU/mL). Epstein-Barr virus (EBV) IgG was positive, but IgM was negative. Hepatitis A/B, herpes simplex virus (HSV), and varicella tests were negative. DMF was paused for 3 months, and antiviral therapy led to reduced liver enzymes and CMV DNA levels. MS remained stable without new MRI lesions. Conclusion: DMF therapy may contribute to CMV infection despite the patient's normal lymphocyte counts. It may be beneficial with routinely test with viral panel with patients with progression in MS. Further studies are needed to clarify the risk of CMV infection in DMF-treated MS patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.